New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 presented at the AHA Scientific Sessions 2024
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced new preclinical data indicating that drug candidate CS585, a novel prostacyclin (IP) receptor agonist, inhibits platelet activation and clot formation up to 24 hours post-administration. The new data was presented at the AHA Scientific Sessions 2024, in Chicago on November 16, 2024.
“We are delighted to present additional data for our preclinical asset CS585, demonstrating that the drug candidate, a novel IP receptor agonist, sustainably inhibits platelet activation and clot formation for extended periods. These new results add to our strong belief that CS585 has characteristics that suggests its relevance as a novel anti-platelet therapeutic with potential to treat thrombotic diseases,“ said Sten R. Sörensen, CEO, Cereno Scientific
The abstract titled “Sustained Anti-Thrombotic Efficacy Of CS585, A Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential”, was authored by L. Stanger, M Flores, P Yalavarthi and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific, Gothenburg, Sweden.
The abstract was presented by Livia Stanger, Graduate student at the Holinstat Lab at University of Michigan, led by Dr. Michael Holinstat, Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan. Dr. Holinstat leads Cereno’s development programs at the University of Michigan and is Director of Translational Research at Cereno.
Read the full abstract here.
The timeframe of effect of CS585, iloprost, and selexipag in mice following a single IV dose was evaluated. Inhibition of thrombus formation was measured ex vivo in whole blood under arterial shear rates. In vivo, CS585, iloprost, or selexipag, were administered prior to labeling of platelets and fibrin. Thrombus formation at the site of injury was measured using the cremaster arteriole injury thrombosis assay.
CS585 administered to mice prior to blood draw decreases platelet adhesion and blood clot formation under arterial shear conditions. These effects are observed up to 24 hours post-administration; however, the effects of iloprost and selexipag return to pre-treatment levels by 24 hours. In vivo, mice administered iloprost or selexipag demonstrated a decrease in platelet accumulation and fibrin formation, however the effects were abrogated post-administration by 10 minutes and 4 hours, respectively. Administration of CS585, however, demonstrated sustained inhibition of thrombus formation at the site of injury, with inhibitory effects observed at 18 hours post-administration.
About AHA
AHA (American Heart Association) Scientific Sessions is open to scientists, clinicians, researchers, and healthcare professionals from all over the world. It provides a platform to discuss cutting-edge topics, including electrophysiology innovations, cardiology in athletes, and groundbreaking first-in-human therapeutics. The scientific sessions will cover the latest developments in cardiovascular health, scientific and clinical discussions, and other topics aimed at fostering innovation and participation from attendees.
About CS585
Drug candidate CS585 is an oral, highly potent, and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. A target indication for CS585 is currently being evaluated; rare diseases with high unmet medical needs are being considered.
A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.
In early November 2023, CS585 was highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding.
New preclinical data for Cereno Scientific’s novel IP Receptor Agonist CS585 was presented at ESC Congress 2024, indicating that CS585 inhibits platelet activation and clot formation up to 24 hours post-administration.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: henrik.westdahl@cerenoscientific.com
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.
The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information is on www.cerenoscientific.com.